Skip to main content
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses

New Research In

Physical Sciences

Featured Portals

  • Physics
  • Chemistry
  • Sustainability Science

Articles by Topic

  • Applied Mathematics
  • Applied Physical Sciences
  • Astronomy
  • Computer Sciences
  • Earth, Atmospheric, and Planetary Sciences
  • Engineering
  • Environmental Sciences
  • Mathematics
  • Statistics

Social Sciences

Featured Portals

  • Anthropology
  • Sustainability Science

Articles by Topic

  • Economic Sciences
  • Environmental Sciences
  • Political Sciences
  • Psychological and Cognitive Sciences
  • Social Sciences

Biological Sciences

Featured Portals

  • Sustainability Science

Articles by Topic

  • Agricultural Sciences
  • Anthropology
  • Applied Biological Sciences
  • Biochemistry
  • Biophysics and Computational Biology
  • Cell Biology
  • Developmental Biology
  • Ecology
  • Environmental Sciences
  • Evolution
  • Genetics
  • Immunology and Inflammation
  • Medical Sciences
  • Microbiology
  • Neuroscience
  • Pharmacology
  • Physiology
  • Plant Biology
  • Population Biology
  • Psychological and Cognitive Sciences
  • Sustainability Science
  • Systems Biology
Introduction

Vaccines: Science, health, longevity, and wealth

Rino Rappuoli
PNAS August 26, 2014 111 (34) 12282; first published August 19, 2014; https://doi.org/10.1073/pnas.1413559111
Rino Rappuoli
Novartis Vaccines, 53100 Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rino.rappuoli@novartis.com
  • Article
  • Info & Metrics
  • PDF
Loading

Vaccination is considered the most successful and cost-effective medical intervention ever introduced (1). A recent publication from the US Centers for Disease Control and Prevention suggests that this distinction continues to hold, reporting that for children born in the United States during the period 1994–2013 vaccines will have prevented 322 million illnesses, 21 million hospitalizations, and 732,000 premature deaths, saving $295 billion in direct medical costs and $1.38 trillion in total societal costs (2). In a period of technological revolution and limited resources, we may think that our society would prioritize investing in the field of vaccine development insofar as it simultaneously protects health and saves money. Unfortunately, this is not the case and the future of vaccines is in jeopardy.

The special issue of the centenary of PNAS provides an opportunity to review the history of vaccines, the most exciting features of vaccine science, and to contemplate the future. The picture that emerges is intriguing: The history of vaccines confirms that vaccines have been the medical intervention with the greatest beneficial impact on human health and longevity (3). Vaccines dramatically reduced the incidence of infectious diseases that historically killed hundreds of millions, and made a substantial contribution to life expectancy that during the last century in developed countries increased from ∼47–80 y (4). During the last 30 y, improvements in our understanding of immunology and technological progress involving recombinant DNA, conjugation technology, and genomics provided vaccines against diseases, which could not be conquered by conventional vaccine technologies. Finally, new, emerging, more powerful technologies, including rationally designed adjuvants and systems biology (4⇓–6), raise the possibility of new and better vaccines that may allow better control of existing diseases and extend the benefits of vaccination to newly emerging infectious diseases and to noncommunicable diseases as well.

In the next few decades vaccines have the potential to continue to be the most powerful tool for advancing global health and contributing to human well-being by (i) extending the benefits of vaccination beyond childhood and especially among pregnant women and the elderly; (ii) providing tools to prevent and control emerging infections, such as pandemic influenza and HIV; (iii) preventing and controlling noncommunicable diseases, such as cancer, neurodegenerative, autoimmune, and metabolic disorders that are the leading causes of morbidity and mortality in modern society; (iv) extending the benefits of vaccination to low-income countries so that during the next two decades we can close the health and longevity gap between poor and rich countries (4, 7); and (v) controlling most of the existing, and reducing the emergence of, antibiotic-resistant bacteria (8).

The bitter truth is that although vaccines keep people healthy and save money, fewer and fewer pharmaceutical companies invest in the development of new vaccines. Rather, their investment dollars are channeled disproportionately to new drug therapies in areas such as oncology, immunology, inflammation, and cardiovascular, metabolic, and neurodegenerative diseases, for which the return on investment tends to be higher and more predictable than for vaccines. A large part of the problem lies with the cost-effectiveness models policymakers commonly use to value vaccines, which demonstrate the cost-effectiveness of modestly priced vaccines that prevent large numbers of cases of mild diseases, but not of more costly vaccines that prevent rarer and often life-threatening diseases (9). The consequence is that industry, to maximize shareholder returns, prioritizes investments in therapies and deprioritizes investment in vaccines.

How did we end up in this situation, in which the allocation of resources for medical research is increasingly skewed against vaccines? The problem lies partly in the cost-effectiveness approach, which typically accounts for averted medical care costs and loss of parental work time to care for sick children, and not the full benefits of health to such items as lifetime income and wealth accumulation, and its economic spillover effects on the broader society. Several initiatives are trying to radically change the economic evaluation of vaccines; these are described in an article on valuing vaccination in this special issue (10), in the SMART Vaccines initiative of the Institute of Medicine that describes 28 attributes to be considered in vaccine prioritization (11), and in ref. 9. Understanding the value of vaccines to our society and taking this value properly into account in the allocation of resources to vaccine development are both essential to realizing the continuing contribution vaccines can make to human well-being and progress.

Footnotes

  • ↵1Email: rino.rappuoli{at}novartis.com.
  • Author contributions: R.R. wrote the paper.

  • Conflict of interest statement: R.R. is a full-time employee of Novartis Vaccines.

  • This article is part of the special series of PNAS 100th Anniversary articles to commemorate exceptional research published in PNAS over the last century.

References

  1. ↵
    1. Berkley S
    (2014) Improving access to vaccines through tiered pricing. Lancet 383(9936):2265–2267.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Whitney CG,
    2. Zhou F,
    3. Singleton J,
    4. Schuchat A
    (2014) Benefits from immunization during the vaccines for children program era—United States, 1994–2013. MMWR Morb Mortal Wkly Rep 63(16):352–355.
    OpenUrlPubMed
  3. ↵
    1. Plotkin S
    (2014) History of vaccination. Proc Natl Acad Sci USA 111:12283–12287.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Rappuoli R,
    2. Pizza M,
    3. Del Giudice G,
    4. De Gregorio E
    (2014) Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA 111:12288–12293.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Maisonneuve C,
    2. Bertholet S,
    3. Philpott DJ,
    4. De Gregorio E
    (2014) Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 111:12294–12299.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Pulendran B
    (2014) Systems vaccinology: Probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci USA 111:12300–12306.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. MacLennan CA,
    2. Saul A
    (2014) Vaccines against poverty. Proc Natl Acad Sci USA 111:12307–12312.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Callaway E
    (2014) Hidden bonus from vaccination. Nature 512:14–15.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Black S
    (2013) The role of health economic analyses in vaccine decision making. Vaccine 31(51):6046–6049.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bärnighausen T,
    2. Bloom DE,
    3. Cafiero-Fonseca ET,
    4. O’Brien JC
    (2014) Valuing vaccination. Proc Natl Acad Sci USA 111:12313–12319.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    National Academies Press (2013) Smart Vaccines: Strategic Multi-Attribute Ranking Tool for Vaccines. Available at www.nap.edu/smartvaccines. Accessed August 1, 2014.
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vaccines: Science, health, longevity, and wealth
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vaccines: Science, health, longevity, and wealth
Rino Rappuoli
Proceedings of the National Academy of Sciences Aug 2014, 111 (34) 12282; DOI: 10.1073/pnas.1413559111

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Vaccines: Science, health, longevity, and wealth
Rino Rappuoli
Proceedings of the National Academy of Sciences Aug 2014, 111 (34) 12282; DOI: 10.1073/pnas.1413559111
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley
Proceedings of the National Academy of Sciences: 111 (34)
Table of Contents

Submit

Sign up for Article Alerts

Article Classifications

  • Biological Sciences
  • Medical Sciences

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

You May Also be Interested in

Surgeons hands during surgery
Inner Workings: Advances in infectious disease treatment promise to expand the pool of donor organs
Despite myriad challenges, clinicians see room for progress.
Image credit: Shutterstock/David Tadevosian.
Setting sun over a sun-baked dirt landscape
Core Concept: Popular integrated assessment climate policy models have key caveats
Better explicating the strengths and shortcomings of these models will help refine projections and improve transparency in the years ahead.
Image credit: Witsawat.S.
Double helix
Journal Club: Noncoding DNA shown to underlie function, cause limb malformations
Using CRISPR, researchers showed that a region some used to label “junk DNA” has a major role in a rare genetic disorder.
Image credit: Nathan Devery.
Steamboat Geyser eruption.
Eruption of Steamboat Geyser
Mara Reed and Michael Manga explore why Yellowstone's Steamboat Geyser resumed erupting in 2018.
Listen
Past PodcastsSubscribe
Multi-color molecular model
Enzymatic breakdown of PET plastic
A study demonstrates how two enzymes—MHETase and PETase—work synergistically to depolymerize the plastic pollutant PET.
Image credit: Aaron McGeehan (artist).

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Librarians
  • Press
  • Site Map
  • PNAS Updates

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490